Is it appropriate to prescribe gabapentin for a patient with a history of substance abuse?

Gabapentin Prescribing in Patients with Substance Use History

Gabapentin can be prescribed to patients with a history of substance abuse, but requires heightened vigilance, careful patient selection, and close monitoring due to documented misuse potential, particularly in those with active or recent polysubstance use disorders. 1

Key Evidence from FDA Labeling

The FDA label explicitly acknowledges that gabapentin misuse and abuse occur, particularly in individuals with polysubstance abuse history 1. The label mandates that prescribers:

• Carefully evaluate patients for a history of drug abuse before prescribing
• Observe for signs of misuse or abuse (tolerance development, self-dose escalation, drug-seeking behavior)
• Recognize that most reported cases involved higher-than-recommended doses for unapproved uses 1

Risk Stratification Algorithm

High-Risk Patients (Avoid or Use Extreme Caution):

• Active opioid use disorder (40-65% misuse rate in prescription holders) 2
• Current polysubstance abuse
• Recent history of opioid, cocaine, or alcohol abuse 3
• Concurrent benzodiazepine or opioid prescriptions 4, 5

Moderate-Risk Patients (Prescribe with Enhanced Monitoring):

• Remote substance use history (>2 years abstinent)
• Smoking, alcohol use, or antidepressant use 6
• Living alone, anxiety, or depression 6

Lower-Risk Patients:

• No substance use history
• Stable social support
• Clear medical indication (epilepsy, neuropathic pain)

Critical Safety Considerations

The most concerning finding is increased patient harm when gabapentin is combined with opioids, including:

• Dangerous respiratory depression 4
• Increased opioid-related overdose mortality 5
• Increased hospital utilization 5

Importantly, pure gabapentin overdoses are relatively safe, but become lethal when mixed with opioids or sedatives 7. This is particularly relevant given that 26.8% of gabapentinoid-positive cases also test positive for THC, and 46.8% for methamphetamine 8.

Prescribing Guidelines

If prescribing is deemed necessary:

1. Start with lowest effective dose - Most abuse cases involve >3000 mg/day (range 600-8000 mg/day) 3
2. Limit initial prescription duration - National guidance emphasizes avoiding long-term use without clear benefit 4
3. Implement prescription monitoring - Check state prescription drug monitoring programs
4. Schedule frequent follow-ups - Weekly to biweekly initially
5. Avoid concurrent CNS depressants - Particularly opioids and benzodiazepines

Monitoring for Misuse

Watch for these red flags:

• Self-dose escalation beyond prescribed amounts
• Early refill requests
• "Lost prescription" claims
• Concurrent use of multiple controlled substances
• Withdrawal symptoms (agitation, disorientation, confusion) occurring 12 hours to 7 days after discontinuation 1, 3

Evidence Quality and Nuances

The 2019 Lancet Psychiatry guideline [4-4] represents the highest-quality evidence, showing that 53% of gabapentinoid users in England had continuous prescriptions for ≥12 months, a practice of "doubtful efficacy in many cases." This large national database study (855,680 gabapentinoid users) provides robust epidemiological evidence.

Pregabalin appears more addictive than gabapentin regarding behavioral dependence symptoms and self-administration patterns 7. However, both carry risk in vulnerable populations.

The systematic reviews 5, 7, 2 consistently identify opioid use disorder as the greatest risk factor for gabapentinoid abuse, with prevalence rates of 15-22% in opioid-using populations versus 1% in the general population.

Common Pitfalls to Avoid

1. Assuming gabapentin is "safe" because it's not scheduled - This outdated belief ignores substantial misuse evidence
2. Prescribing without checking substance use history - The single most important risk factor
3. Long-term prescribing without reassessment - Half of patients remain on these medications for years 4
4. Ignoring concurrent opioid prescriptions - This combination significantly increases mortality risk 5

Bottom Line

Gabapentin is not contraindicated in substance use history, but the decision requires individualized risk assessment. In patients with active polysubstance use or opioid use disorder, alternative treatments should be strongly considered. When prescribed, implement strict monitoring protocols and avoid concurrent opioid prescriptions whenever possible.